<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table5" position="float"><label>Table 5.</label><caption><title>Adverse events of patients receiving TILA-TACE or cTACE.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Adverse events*</th><th valign="top">TILA-TACE</th><th valign="top">cTACE<sup>&#8224;</sup></th></tr></thead><tbody><tr><td valign="top"><bold>Pain</bold></td><td valign="top">5 out of 30</td><td valign="top">3 out of 27</td></tr><tr><td valign="top"><bold>Fever (&#8805;38.5)<sup>&#8225;</sup></bold></td><td valign="top">13 out of 30</td><td valign="top">9 out of 27</td></tr></tbody></table><table-wrap-foot><fn><p>* The adverse events monitored also include acute hepatic decomposition, irreversible hepatic decompensation, respiratory failure or decompensation, biliary stricture or obstruction, liver abscess, gastrointestinal bleeding, arterial thrombosis, arterial-portal shunting. These events were not observed in the patients.</p><p><sup>&#8224;</sup> Patients were retrospectively retrieved from our database.</p></fn><fn><p><sup>&#8225;</sup> Mild fever occurred to all patients.</p></fn></table-wrap-foot></table-wrap>